DF
UTHR icon

Donoghue Forlines’s United Therapeutics UTHR Stock Holding History

Donoghue Forlines’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,134
Closed -$1.48M – 268
2024
Q3 		$1.48M Buy
+4,134
New +$1.4M 0.42% 67
2021
Q3 		– Sell
-3,342
Closed -$600K – 244
2021
Q2 		$600K Sell
3,342
-112
-3% -$21.3K 0.11% 172
2021
Q1 		$578K Sell
3,454
-519
-13% -$86.5K 0.11% 176
2020
Q4 		$603K Buy
+3,973
New +$521K 0.12% 190

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Donoghue Forlines's UTHR Position: Q4 2024 in Review

Donoghue Forlines sold out of United Therapeutics (UTHR) in Q4 2024, closing a stake of 4,134 shares — an estimated $1.48M sold.

Donoghue Forlines first reported a position in UTHR in Q4 2020 and held it in 4 quarters. The position peaked at $1.48M in Q3 2024. 673 funds tracked by Wall St. Rank hold UTHR as of Q4 2024.

  • Donoghue Forlines reported no remaining United Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Donoghue Forlines sold 4,134 United Therapeutics shares in Q4 2024, an estimated $1.48M.
  • Donoghue Forlines first reported a position in United Therapeutics in Q4 2020 and held it in 4 quarters.
  • Donoghue Forlines's United Therapeutics position peaked at $1.48M in Q3 2024.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2024.

Based on Donoghue Forlines's 13F filing for Q4 2024, filed 17 Jan 2025.